A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Patients With Chronic Genotype 1 Hepatitis C.

Trial Profile

A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Patients With Chronic Genotype 1 Hepatitis C.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs TG 4040 (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms HCVac
  • Sponsors Transgene
  • Most Recent Events

    • 28 Apr 2013 Final results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 24 Apr 2013 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2013 Final results will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013), according to a Transgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top